Gyre Therapeutics vs Zevra Therapeutics
GYRE and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GYRE and ZVRA compare
Gyre Therapeutics and Zevra Therapeutics are about the same size, with market caps of $508M and $558M.
Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −3.7% for Gyre Therapeutics).
Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −33.9% at Gyre Therapeutics.
Zevra Therapeutics scores higher on the StockData Score (15 against 11 for Gyre Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GYRE | ZVRA |
|---|---|---|
| Size and price | ||
| Market cap | $508M | $558M |
| Share price | $4.56 | $9.40 |
| Change, 1 year | −42.9% | 5.9% |
| Change, 5 years | −75.7% | 16.8% |
| Beta (5Y) | 1.21 | 1.16 |
| Employees | 618 | 61 |
| StockData Score | ||
| Total score | 11 | 15 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 10.1× |
| P/S | 4.7× | 4.1× (better) |
| P/B | 4.7× | 2.6× (better) |
| EV/EBITDA | – | 4.0× |
| P/FCF | – | 17.1× |
| FCF yield | −1.5% | 5.8% (better) |
| Fair value | $5.29 | $23.57 |
| Margin of safety | 13.8% | 60.1% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.7% | 119% (better) |
| Revenue growth, 5Y average | 41.0% | 51.6% (better) |
| Net income growth (TTM) | −801% | 2104% (better) |
| Profitability | ||
| Gross margin | 93.4% | 95.5% (better) |
| Operating margin | −14.4% | 60.5% (better) |
| Net margin | −33.9% | 42.8% (better) |
| FCF margin | −7.2% | 24.0% (better) |
| Return on equity | −34.9% | 34.8% (better) |
| Return on invested capital | −26.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Net debt / EBITDA | – | −2.64 |
| Interest coverage | – | 14.4× |
| Current ratio | 4.32 | 5.17 (better) |
| Altman Z-score | 8.53 (better) | 4.35 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.8% | 78.5% |
| Held by insiders | 93.8% | 1.2% |
| Insider net buying, 12 months | −$953K (better) | −$2.5M |
| Short interest, % of float | 32.4% | 11.2% |
Go deeper
- GYRE stock overview
- GYRE income statement
- GYRE valuation and score
- ZVRA stock overview
- ZVRA income statement
- ZVRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.